Susan G. Komen Announces 4 New Members of Board of Directors

Four global leaders have been appointed to the board of directors at Susan G. Komen, the world’s leading breast cancer organization.

Komen said that with a combined expertise in oncology, finance, and technology investment, the addition of Kim Blackwell, Elizabeth de-Saint Aignan, Charles Rockefeller, and Kathy Sutherland underscores the organization’s commitment to crafting a dynamic and influential leadership team, poised not just for change, but to spearhead transformative initiatives.

“Komen’s new board members join a legacy of passionate individuals who have dedicated themselves to making a difference,” said Paula Schneider, president & CEO of Susan G. Komen. “As I often say, ending breast cancer will take a village—and with these four new powerhouse leaders on board, we are sure to amplify our impact on the lives of countless families nationwide, positioning us to make even greater strides in our mission to end breast cancer forever.”

The organization said the appointments are a significant milestone in its continued commitment to advancing breast cancer research, awareness, and support. The newly appointed board members bring a wealth of experience and expertise to the organization, further fortifying Komen’s mission to end breast cancer forever.

New board members

Here’s more on the appointees from Komen:

Blackwell, CEO at Zentalis Pharmaceuticals, joins the board with an impressive background in oncology clinical development. Her tenure at Duke University Cancer Institute and leadership roles in the pharmaceutical industry showcase her commitment to advancing cancer research and treatment.
de-Saint Aignan, general partner and head of North America for Late Stage Growth Fund at AVP, is a seasoned private equity and venture capital investor with 25 years of experience investing in rapidly growing technology companies. She is currently responsible for AVP’s Late Stage Growth Equity Fund.
Rockefeller, CuraPatient Inc. co-founder, brings pioneering expertise in innovative AI-enabled digital health platforms. CuraPatient, utilized by the U.S. Department of Veterans Affairs, offers intuitive care plans, patient engagement tools, and automated administration. Recognized for its top-tier cybersecurity and government interoperability, CuraPatient is among just 21 companies with FedRamp High certification. It also won first prize in a Tech Sprint competition hosted by the National Institute of Artificial Intelligence, cementing its leadership in healthcare innovation.
Sutherland, partner & CEO at GoldenTree Asset Management, brings a wealth of financial acumen and strategic leadership to the board. She is also a member of GoldenTree’s Executive Committee. Sutherland oversees the firm’s global strategy, product and business development, and long-term planning. Formerly Managing Director at J.P. Morgan, she led Fund and Structured Product Distribution across the Americas, Europe, the Middle East and Asia.

Ed Dandridge, EVP & chief marketing/communications officer at AIG, will continue to serve as the chairman of the board and Jerri Johnson, VP of Workforce Management Technology at Sony Pictures Entertainment, as vice chair of the board.

Get on the list.
Dallas Innovates, every day.

R E A D N E X T

Kanarys Inc. Appoints Google's Chief Diversity Officer to Its Board of Directors
"Since data is crucial for maintaining ongoing DEIB initiatives and dedication, Kanarys leads the way in establishing quantifiable DEIB strategies, thanks to its data-centric methodology aimed at creating a fairer future for all work settings," says Google CDO and Kanary's Board Member Melonie Parker.
Dallas-Based Susan G. Komen Launches National Breast Cancer Research Registry
Dallas-based Susan G. Komen—one of the world's leading nonprofits raising money for breast cancer research, awareness and community programs—has launched a cloud-based research platform specifically for breast cancer patients and survivors to share their personal health data with the organization. The data will be used to accelerate breast cancer research and help discover cures for breast cancer.
Noted Dallas Researcher, Physician Named as Susan G. Komen Research Scholar
Carlos L. Arteaga, M.D., is director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of oncology programs at UT Southwestern Medical Center. He is a professor of internal medicine and the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology at UT Southwestern.
Plano Consulting Firm BGSF Expands Its Board of Directors
Plano-based BGSF Inc., a growing provider of consulting, managed services, and professional workforce solutions, expanded its board of directors to seven members with the appointment of Donna Carroll. “We are excited to welcome Donna to the BGSF’s Board of Directors. Her passionate leadership and deep industry experience further strengthens our organization. I look forward to working with Donna as we continue to advance the company’s long-term growth strategy and our ability to drive long term shareholder returns,” Chair, President and CEO Beth Garvey said in a statement. Carroll is a 30-year veteran and leading strategic thinker and innovator in the…
Capital One Executive Joins Khan Academy Board of Directors
Sanjiv Yajnik, president of financial services at Capital One, joins Khan Academy's board after years of seeing its influence on his own family. With more than 160 million users worldwide, the academy seeks to provide a free, world-class education to anyone, anywhere.